On this page
How do you organize a nonclinical ADME report?
Organize the report around its absorption, distribution, metabolism or excretion question and identify the measured analyte, test system, sampling and analytical method. Present the actual results and calculation basis before interpreting disposition. Distinguish parent drug, metabolites, total radioactivity and unbound measurements wherever their meanings differ.
Before you begin
Acquired nonclinical disposition evidence. Human PK studies and clinical dose recommendations are outside this preparation guide.
What you will prepare: A reproducible disposition report whose concentrations, derived parameters and limitations agree with the source records.
Assign the disposition question and source records
The pharmacokinetics family separates absorption (4.2.2.2), distribution (4.2.2.3), metabolism (4.2.2.4) and excretion (4.2.2.5). Analytical validation and interaction work have their own locations. Use 4.2.2.7 for other PK studies only after identifying the specific question and why a more descriptive location does not fit.
Obtain the protocol, test-article and formulation identity, dosing and sampling records, biological matrices, analytical reports and analysis outputs. Define each reported analyte: parent drug, metabolite, total radioactivity or another measurement. Do not collapse chemically different quantities into a single “drug level” column.
Write absorption around the actual route and sampling design
Describe administered dose and formulation, route, sampling schedule, analyzed population and the concentration-time data used for calculations. Explain actual versus nominal sample times and handling of unquantifiable or missing values. Identify the exposure parameters that were estimable and the method used to derive them.
When reporting a comparative availability conclusion, identify both comparison conditions and the calculation basis. An oral concentration-time curve alone does not document an absolute-bioavailability comparison. If a reference arm is absent, describe the information actually available rather than filling in a percentage from another experiment.
Keep tissue measurement and pharmacological exposure distinct
For distribution studies, identify the tissue or compartment, collection time, measurement method and units. Explain the relationship between the measured signal and the chemical entity of interest. For binding work, retain the conditions and analytical interpretation that distinguish total from unbound concentrations.
Fictional example: a tissue study detects radioactivity in brain, and the draft states that active parent drug crosses into brain at an effective concentration. The observation does not by itself identify the chemical form or prove pharmacological activity. Request the relevant characterization, or narrow the conclusion to the actual measured signal. Carry the same distinction into the summary.
Describe metabolic identity and the limits of comparison
For metabolism, explain the biological system, species or donor material, incubation or dosing conditions, analytical approach and the basis for metabolite assignments. Distinguish confirmed structure from a tentative signal assignment. Identify which comparisons used matched methods and which depend on different analytical coverage.
A useful result table separates analyte identity, evidence supporting the identity, relative or absolute measurement and unresolved characterization. Ask the scientist to interpret relevance across species; the author should not infer that two peaks with similar retention times are the same metabolite.
Account for recovery and explain unusual PK tasks
For excretion, report collection intervals and routes, the recovered material, the calculation denominator and unaccounted fractions. Keep parent-drug recovery separate from total-radioactivity recovery. Explain missing samples and incomplete collection rather than forcing totals to match an expected mass balance.
For another PK task at 4.2.2.7, state the unique objective, such as an experimental disposition relationship not captured by the main categories, and preserve the methods and limitations needed to evaluate it. The heading is not a miscellaneous inbox. Reconcile all derived values with the controlled analytical and calculation outputs before the results feed Module 2.6.4/2.6.5. Study selection and the need for further evidence depend on the program, not on how many headings remain empty.
Define the measured quantity before comparing results
Create a small quantity dictionary for the report and use it consistently in tables, figures and conclusions. This is an editorial reconciliation aid, not an analytical specification.
| Quantity | Define explicitly | Avoid this unsupported substitution |
|---|---|---|
| Parent concentration | Matrix, units and analytical identity | Total radioactivity described as parent drug |
| Metabolite result | Confirmed or tentative identity and measurement basis | Similar chromatographic peaks treated as one structure |
| Unbound fraction | Matrix and binding-assessment conditions | Total concentration treated as free concentration |
| Recovered amount | Collection route, interval and denominator | Percentage of recovered material treated as percentage of dose |
| Exposure parameter | Analyte, time interval and calculation method | Values from different intervals compared as equivalent |
For each proposed cross-study comparison, read the two definitions aloud. If the analyte, denominator or interval differs, identify the scientific bridge before comparing the values. A shared unit is insufficient: two concentrations in the same units can represent different chemical entities or populations.
Fictional arithmetic check: 60 units are recovered from an administered 100-unit amount, and one fraction contains 30 units. That fraction is 50% of recovered material but 30% of the administered amount. Neither description proves complete recovery. State the actual basis and the unaccounted amount; have the study scientist assess the significance of incomplete collection.
Reconcile the dictionary with the analytical reports and retain its distinctions in the PK summaries. A summary should simplify the presentation without changing what was measured.
Your preparation checklist
0/5 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does tissue radioactivity establish active parent-drug exposure?
Not by itself. A radioactive signal may include parent drug and other labeled material. Identify what the method distinguishes and what supporting characterization exists. The report should describe the measured signal without claiming an active parent concentration or pharmacological effect that was not established.
Can an oral concentration curve establish absolute bioavailability?
An oral curve alone does not document the reference comparison needed for an absolute-bioavailability conclusion. Identify the actual comparison conditions and calculation basis. If the required evidence is absent, report the oral exposure findings without inventing an absolute percentage.
Where do nonclinical PK interaction studies belong?
The FDA hierarchy provides 4.2.2.6 for pharmacokinetic drug interaction reports. Keep their disposition question distinct from pharmacodynamic interactions at 4.2.1.4. If one controlled study addresses both, use an agreed main location and cross-references that preserve the relationship between its findings.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Technical specification
FDA eCTD v4.0 headings and hierarchy ↗Version 2.2, February 2025; Module 4, printed pages 6–10. Technical placement and allowable document types, not a required-study list. Checked September 22, 2026.
Guidance
FDA ICH M10: bioanalytical method validation and study sample analysis ↗Final guidance, November 2022; scope I.C (1.3) and section VIII (8), especially 8.1 and Table 1. Excludes biomarker and immunogenicity bioanalysis; distinguishes site records from submitted report content. Checked September 22, 2026.
Guidance
ICH M3(R2): nonclinical safety studies ↗Step 4, June 11, 2009; sections 1–5, 8–17. Development context and timing, not an automatic requirement for each heading. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 4.2.2. A heading identifies placement, not mandatory applicability.